{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:59:38Z","timestamp":1791377978301,"version":"4.3.2"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115428","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T16:48:57Z","timestamp":1745340537000},"page":"115428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-8403","authenticated-orcid":false,"given":"Ali","family":"Shamseddine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Turfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laudy","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef H.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"El Husseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Kreidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-3712","authenticated-orcid":false,"given":"Youssef","family":"Bouferraa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-6749","authenticated-orcid":false,"given":"Charbel","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4576-6248","authenticated-orcid":false,"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5320","authenticated-orcid":false,"given":"Ibrahim","family":"Khalifeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0192-5828","authenticated-orcid":false,"given":"Deborah","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8995-7946","authenticated-orcid":false,"given":"Sally","family":"Temraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Shaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaad","family":"Soweid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kholoud","family":"Alqasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rula","family":"Amarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala Al","family":"Awabdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Deeba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Doughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousa","family":"El khaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Daoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Al","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Dabous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-7162","authenticated-orcid":false,"given":"Ahmad","family":"Hushki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faek","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1270-610X","authenticated-orcid":false,"given":"Maya","family":"Charafeddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monita Al","family":"Darazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Geara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115428_bib1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/annonc\/mdw062","article-title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d75 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study","volume":"27","author":"Bujko","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2407-13-279","article-title":"Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial","volume":"13","author":"Nilsson","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.115428_bib3","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115428_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/bjs.1800700805","article-title":"The quality of life after rectal excision for low rectal cancer","volume":"70","author":"Williams","year":"1983","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2025.115428_bib5","doi-asserted-by":"crossref","first-page":"e1555","DOI":"10.1002\/onco.13824","article-title":"Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis","volume":"26","author":"Liu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2025.115428_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","article-title":"Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Breugom","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: long-term results of UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib10","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib11","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115428_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.663852","article-title":"Immunotherapy combined with radiation therapy for genitourinary malignancies","volume":"11","author":"Ukleja","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib13","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.3390\/cancers15215124","article-title":"Implications of rectal cancer radiotherapy on the immune microenvironment: allies and foes to therapy resistance and patients' outcome","volume":"15","author":"Sartorius","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115428_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00262-019-02458-x","article-title":"Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer","volume":"69","author":"Bains","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2025.115428_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1186\/s12885-020-07333-y","article-title":"Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma","volume":"20","author":"Shamseddine","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.115428_bib17","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115428_bib18","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO Trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2025.115428_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ejca.2025.115428_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115428_bib21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41416-024-02730-7","article-title":"Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"131","author":"Tsukada","year":"2024","journal-title":"Br J Cancer"},{"issue":"4_","key":"10.1016\/j.ejca.2025.115428_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2023.41.4_suppl.7","article-title":"Long-term results from NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)","volume":"41","author":"George","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3_","key":"10.1016\/j.ejca.2025.115428_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2021.39.3_suppl.8","article-title":"NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)\u2014Pembrolizumab experimental arm (EA) primary results","volume":"39","author":"Rahma","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115428_bib25","doi-asserted-by":"crossref","first-page":"S1266","DOI":"10.1016\/j.annonc.2023.10.017","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann Oncol"},{"issue":"15_","key":"10.1016\/j.ejca.2025.115428_bib26","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2021.39.15_suppl.3511","article-title":"Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study","volume":"39","author":"Salvatore","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115428_bib27","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3390\/cancers13061374","article-title":"Emerging trends for radio-immunotherapy in rectal cancer","volume":"13","author":"Corr\u00f2","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115428_bib28","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejca.2025.115428_bib29","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115428_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1789032","article-title":"The consensus immunoscore: toward a new classification of colorectal cancer","volume":"9","author":"Lanzi","year":"2020","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.ejca.2025.115428_bib31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:58:01Z","timestamp":1749815881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"alternative-id":["S0959804925002096"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115428","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115428"}}